Cymbalta Withdrawal Solution, Sertraline Side Effects, Treatment Options

Cymbalta Withdrawal Symptoms

The majority of people attempting Cymbalta withdrawal experience an antidepressant withdrawal syndrome. This is also known as Cymbalta discontinuation syndrome in the United States. In Europe it is call Cymbalta withdrawal side effects. The F.D.A. estimates 10% of those experiencing Cymbalta withdrawal will go back up on the Cymbalta because the withdrawal symptoms are too severe. If you want to read the short version of how to handle Cymbalta withdrawal side effects Click here. Page opens new browser window. The most common and debilitating Cymbalta withdrawal side effect is called "brain zaps." Brain zaps are described by people experiencing it as a; electrical jolt that tends to run from base of the neck up into their head. Another side effect that tends to run with brain zaps is a shiver, a feeling as your head is floating, dizziness, and/or a whirling sensation in the head. These symptoms can come in waves or even be persistent. The good news; in 2002, our founder, Jim Harper, discovered the correct type of Omega 3 taken in the right quantity will eliminate these devastating head symptoms quickly. Usually within a couple of hours. The body in a normal state uses the oil from our diet, specifically from omega 3 found in fish, to build and replenish the end point of areas in the brain that sends and receives electrical signals. We are using easy to understand terminology here so it is easy to understand. Let's leave the technical jargon to physicians. These brain zaps have nothing to do with serotonin levels or other made up reasons. It is simple really; our body works in a very natural way with how it uses amino acids, proteins, fats in food and all other diet items to maintain a balance. When you introduce any toxin that disrupts these processes the body reacts. The most common Cymbalta withdrawal symptoms reported include: Flu like symptoms Insomnia Anxiety Brain zaps Tremors Diarrhea Vomiting Increased suicidal ideation Nausea Headache Mania Hypomania Ringing in the ears Aggression Confusion Imbalance Mood swings Please note: These are the most common Cymbalta withdrawal side effects but far from all potential Cymbalta withdrawal side effects. There is a warning the FDA has put a black box warning on Cymbalta. WARNING: SUICIDAL THOUGHTS AND BEHAVIORSSee full prescribing information for complete boxed warning. Antidepressants increased the risk of suicidal thoughts and behaviorsin pediatric and young adult patients (5.1) Closely monitor for clinical worsening and emergence of suicidalthoughts and behaviors You may have been prescribed Cymbalta within a very short doctor visit. There was no investigation into other life factors, lab testing, or any conversation about what side effects might present. The failings of this approach may cause quite a burden on the patient. Depression, insomnia, anxiety, fibromyalgia, and other symptoms that Cymbalta is often prescribed for might stem from; diminished vitamin D levels, over active JNK gene, specific proteins that need to be silenced, dietary concerns and food allergies, mitochondrial dysfunction, neurotoxic accumulation, and many other reasons. A full physical from an understanding physician is ideal, before prescribing Cymbalta. Do Your Symptoms Require Cymbalta? The Road Back Program uses nutritional supplements to help with the Cymbalta withdrawal. Most people feel a very fast relief from the Cymbalta withdrawal once they begin taking the supplements and we feel the odds are high; if would have taken nutritional supplements like these before starting the Cymbalta you would have been prescribed the Cymbalta in the first place. In 2007, Jim Harper was giving a speech to a group of psychiatrists in Ireland and during his talk he mentioned his mother just passed away 30 days ago. He went on to describe how he made sure to take his JNK Formula each day to help the body cope with the stress being put on it do to his loss. He went on to say, "The JNK Formula will not remove the emotional loss and how I feel but it will keep the body strong during my time to grieve."

How Do You Survive Cymbalta

Withdrawal?

Surviving Cymbalta withdrawal depends on what you do at this very moment. If you keep doing the same thing you have been doing and you are in a heavy Cymbalta withdrawal, nothing will change for the positive, That is a given. If you decide to do the Cymbalta withdrawal as an inpatient in a drug rehab center DO NOT DO THE 9 DAY PLAN BECAUSE THAT WHAT INSURANCE ALLOWS. Over the past 22 years I have worked with far to many people who were sold on a rehab facility, stayed the 9 days because insurance would only pay for that amount of time. The unscrupulous facility took them off the Cymbalta in 9 days as they promised and by the time the person got off the airplane after their return home they were in full withdrawal. You can't do a Cymbalta withdrawal in 9 days. The Road Back Program can normally help you get back on your feet again but the rehab facility approach of this type is not worth the price you will pay mentally and physically. You will find a few other outpatient Cymbalta withdrawal programs on the internet now and Jim Harper is not aware of one that will cause you harm like the rehab facility's mentioned. However, every other program on the internet was trained by Jim Harper years ago and they are doing what Jim Harper and The Road Back did during that time frame. Almost 2 decades ago Jim Harper trained several physicians and good intentioned people how to get a patient off Cymbalta. Jim went in to detail of the process and what nutritional supplements were used and why they were used. At that time of The Road Back the success rate was not as high as desired and over the following years Jim changed the formulas used with the supplements several times to use new information with DNA testing. Long story short; you will likely wind up using a Cymbalta withdrawal approach The Road Back used in 2003, that was scrapped for something more successful. If you are currently in Cymbalta withdrawal, send Jim Harper an email and he will personally guide you through the process so you can get back on your feet quickly and have a very successful Cymbalta withdrawal. It does not matter if you have been on Cymbalta for 1 month or 20 years. Recovery can happen and the good part is; it does not take more time because you have been taking Cymbalta for years.

When Do Cymbalta Withdrawal

Symptoms Start When

Discontinuing / Quitting Cymbalta?

Cymbalta withdrawal usually begins between day 1 and day 3 of adjusting the Cymbalta. For some people this is not the case but eventually most everyone hits some dosage of the Cymbalta when reducing that jars them. Cymbalta withdrawal begins and they have no idea what they should do. Their physician does not know what to do. They wind up in a spiral downward and wind up on a new medication to try and stop the Cymbalta withdrawal. The best case is the additional drug does that but you are now on 2 drugs instead of only Cymbalta.

What is Cymbalta?

Cymbalta (sertraline) is an antidepressant medication developed in the 1970s with FDA approval granted in 1991. This SSRI drug is prescribed in treating adult depressive disorders (MDD), panic disorder, obsessive compulsory disorders (OCD), social anxiety (SAD), post- traumatic stress disorders (PTSD), and premenstrual dysphoric disorder (PMDD). If you have anxiety before taking Cymbalta, or anxiety begins while taking Cymbalta, odds are the anxiety will continue to get worse. Cymbalta alters dopamine much like the antidepressant Effexor and anxiety is a byproduct of these two drugs.

What Is Cymbalta Used For?

Cymbalta (sertraline) is an antidepressant medication approved to treat adult MDD (major depressive disorder). The Black Box warning on the drug’s packaging mentions that the drug should not be prescribed to anyone under the age of 25, due to heightened risk of suicide. There is an exception to this for patients under the age of 25 who have been diagnosed with OCD (obsessive-compulsive disorder). Potential suicidality is associated with all Cymbalta and may be a concern leading to consider Cymbalta withdrawal, which is recommended to be done always under medical or caregiver monitoring. Adult-only approved uses for the drug provided in a clinical or treatment setting include: MDD: Major Depressive Disorder< PTSD: Post-traumatic stress disorder PD: Panic disorder SAD: Social anxiety disorder OCD: Obsessive-compulsive disorder PMDD: Premenstrual dysphoric disorder

Cymbalta Side Effects

The full list of Cymbalta side effects is quite staggering. In 2004, Jim Harper used the Freedom of Information Act to get the full list of Cymbalta side effects. Jim received the information and it is 500 sheets of letter size paper, single space, a number 10 font size, 3 columns per page. In other words, thousands of known potential Cymbalta side effects were disclosed. Some of the other Cymbalta and Cymbalta withdrawal side effects: Serotonin syndrome: A life- threatening condition requiring immediate medical care in a hospital emergency clinic or ICU. Symptoms to watch for include sudden fever, losing consciousness, inability to move or speak, copious sweating, dilated pupils, chills, tremors, convulsions, diarrhea, agitation, restlessness, racing heart, etc. Suicidal thoughts (common) Suicide attempt (common) Hyperkinesis (muscle spasms, movement disorder) Worsened depression Aggression Paranoia (rare) Anxiety Mania (common) Convulsions Unconsciousness Coma Teeth grinding Akathisia (relentless internal restlessness and discomfort marked by repeated motions, pacing, rocking, etc., that can lead to suicidal thoughts as a means of relief) Tachycardia (racing heart, even when the body is at rest) Rash Itching Burning, crawling feeling in the skin Fever Tics, sudden jerky movements, myoclonus Emotional blunting Behavioral apathy, SSRI- induced-indifference Pain on urination or difficulty urinating Cloudy urine Headache Sexual impairments, i.e., anorgasmia, inability to ejaculate, lowered libido Mood swings Pain around the eyes or eye sockets Sleepiness Bladder pain Prickling skin sensation Numbness Sensory disturbances Insomnia Depersonalization (common) Nervousness Nightmares (paroniria) Hostility Nausea Diarrhea Weight gain Some documented Cymbalta birth defects and injuries include: PPHN or persistent pulmonary hypertension of the newborn, a heart and lung condition which can result in respiratory failure, decreased oxygen to the brain, and multiple organ injuries. Congenital Heart Defects connected to Cymbalta and other SSRIs include ventricular septal defects and atrial septal defects, also referred to as “holes in the heart”, related to heart murmurs, suppressed appetite, breathing difficulties, tiredness, inadequate growth, etc. Increased Risk of Autism has been extensively reported but evidence has not yet been considered conclusive enough for regulatory bodies to ban prescribing to pregnant women. Increased Risk of Clubfoot connected to SSRIs during pregnancy as reported by NIMH, where sertraline exposure had the highest increase in clubfoot of all SSRIs. Increased risk of atrial/ventricular defects and craniosynostosis was reported in a Canadian study from 1998 to 2010 and published in the June 2015 issue of the American Journal of Gynecology & Obstetrics. Cymbalta Withdrawal, What to Expect If using The Road Back Program you should expect to feel a lot better within the first couple days of the program. If you do nothing, expect to continue to feel as you do now. Possibly worse as time goes on. The chance of feeling better if you do nothing is nil. In 1999, The Road Back only had people taper the Cymbalta gradually and slowly. They still suffered. Around 50% could get off the Cymbalta but most went back on the Cymbalta because they continual Cymbalta withdrawal side effects would not diminish or go away. We wish there was a better answer for you than the above but with working with over 19 million people over the last 22 years, the truth is the truth. No way to water it down to make it sound better. Some may think it is just their depression returning but who would not feel depressed if they were still going through Cymbalta withdrawal months after stopping the Cymbalta. We can't stress enough; what you do or do not do at this moment in time is critical for your future. Take your time if at all possible. If you have brain zaps go buy any omega 3 fish oil, even the wrong omega 3 fish oil will help somewhat. While you read this you may want to pause and go take a walk. Look at the trees, the sky or anything off in the distance. Getting your attention off your mind and body may do wonders. Keep this close to your heart; There is Hope and There is a Solution. We are speaking directly to YOU. A 30 day supply of the nutritional supplements will cost you around $80. If you feel it is worth $80 to take a chance that all of this can go away in a couple of days, then take that chance. Over the past 22 years many have sent an email to Jim Harper and said they were not sure what to do about the Cymbalta withdrawal. Even after reading this information. The people that tried something else generally came back within a few months and were in worse shape than before. We do not want this to happen to you. But if is; Jim will still be here to assist. Can Cymbalta Make Depression Worse? Common sense answers this question. If depression is one side effect of taking Cymbalta then Cymbalta can cause depression. You do stand a greater chance of Cymbalta causing depression during withdrawal than while simply taking the Cymbalta as prescribed. The depression during Cymbalta withdrawal can be due to the other Cymbalta withdrawal side effects you are experiencing. Who would not start to get depressed if you have anxiety from morning to night, can't sleep and your head feels like it is on fire. Cymbalta Aggression in Children Children are more prone to aggression when taking Cymbalta than adults. It occurs in 10-20% of children taking any SSRI antidepressant. Two clinical trials performed by Pfizer, aggression was the most common reason noted for Cymbalta discontinuation.

Can You Get Addicted to Cymbalta?

Yes and no. This is where Cymbalta dependence is a matter of wording. Medically speaking in the United States Cymbalta is not addicting. In Europe it is viewed as addicting. The bottom line is; Once you take Cymbalta for 7 days the Cymbalta has made its way through your body. If your body no longer has the Cymbalta in its system, your body will react to the Cymbalta being gone. Much like a person that eats a lot a sweets every day. Your body will react when the sweet substance is not present. Call it addicting, as we would, call it a dependence as United States physicians will, it is what it is. If you do not provide the substance the body reacts and you also have mental feelings that are not positive. We can get into the insulin discussion etc, but we are only talking about a substance being present and then not and the body and mind reacting in a negative manner. What is the difference between Cymbalta and a Benzodiazepine? Cymbalta is an SSRI medication, an antidepressant, used to treat depression and anxiety. Benzodiazepines are prescribed mainly for the treatment of anxiety and panic disorders but also prescribed off-label to treat depression. These two types drug have different chemical components and were designed to work on different brain receptors and neurotransmitters, but some of their effects can be seen to overlap. Benzodiazepines are thought to mainly affect GABA transmission, which can slow the central nervous system to reduce anxiety, while Cymbalta is designed to block the reuptake of serotonin. Benzodiazepines are known to be more prone to dependence/addiction than Cymbalta. While the withdrawal symptoms are similar between both drugs, Cymbalta’s half-life is 22-36 hours, and Benzodiazepines half-life is much lower. Benzodiazepines can have more severe complications if abruptly stopped, including seizures. For safe Benzodiazepine or Cymbalta withdrawal, either of these drugs must be slowly tapered to allow the central nervous system and neurochemistry to safely normalize. Choosing to withdrawal from the Cymbalta first or the benzodiazepine first needs to be evaluated. Use Chapter 23, The Science to decide is part of that equation. Depending on the benzodiazepine you may be taking with the Cymbalta, if you reduce the Cymbalta first it may make you go into withdrawal on the benzodiazepine, even if you did not reduce the benzodiazepine. How long does Cymbalta stay in your system after the last dosage? Our founder, Jim Harper, made great strides with determining this question. Using his DNA testing company in 2004-2005, Jim conducted hundreds of DNA tests to determine how fast or slow medications took to metabolize. In roughly 34 percent of the population the Cymbalta can take as long as 48 hours to clear the body. In others, as little as 8 hours can occur for the Cymbalta to clear the body. Depending on other habits you may have, Cymbalta could clear faster or even take more time than the 48 hours. If you smoke cigarettes and stop smoking while taking Cymbalta, the Cymbalta dosage you are taking will decrease by 15%. On the other side of this, if you start smoking while taking Cymbalta, the Cymbalta dosage will act as though it is 15% higher than you think it is. This is because cigarettes induce an enzyme used to metabolize Cymbalta and anything using that same pathway will shoot though much faster. Caffeine restricts that same enzyme, so if you start or stop drinking coffee while taking Cymbalta you will either go into withdrawal or feel an overdose, even though you have not changed the Cymbalta dosage. This is why The Road Back Program wants you to not change smoking habits or caffeine habits during the Cymbalta taper. Can you overdose on Cymbalta? Yes, it is definitely possible for Cymbalta poisoning to occur. A substantial Cymbalta overdose requires emergency medical intervention to prevent major health problems. This list of Cymbalta overdose symptoms would be the same as those Cymbalta side effects listed above, but more severe. According to the National Institute of Health (NIH), the use of intravenous benzodiazepines is sometimes required during Cymbalta overdose to prevent seizures. Extra cooling measures must be used to reduce hyperthermia, always under the direction of EMT or other medical staff attending to the patient.

Treatment for Cymbalta Withdrawal

Cymbalta has become one of the most frequently prescribed antidepressants in the US. Of equal importance is that depressive disorders have become one of the most frequently diagnosed conditions. These two facts together underscore two important steps toward improved health: Providing safe treatment programs for those who have decided on Cymbalta withdrawal, and Offering drug-free options to regain natural mental health without the need for prescription medications. The Road Back Program was described by Dr. Hyla Cass M.D. in this way: Here's an essential handbook on how to safely and more easily wean yourself (under medical supervision) off the heavily over- prescribed psychotropic medications. I have used the program with my patients and it works!" Hyla Cass M.D. Author of Supplement Your Prescription Send an email to Jim Harper by using the Contact link on the top of this page or read How to Get Off Psychoactive Drugs Safely by Jim Harper and follow the program for Cymbalta withdrawal. Why Jim put his entire book on our website for free is so you can instantly read the material and start this process if you are ready now. One last thing Jim asked us to provide at the bottom of each page of Cymbalta descriptions: There is Hope and There is a Solution REFERENCES Bailey, L.B., Gregory, J.F., (1999). “Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement.” J Nutr 129(5): 919-22. Bailey, L.B., Gregory, J.F., (1999). “Folate metabolism and requirements.” J Nutr 129(4): 779-82. Basile, V.S., Masellis, M., Potkin, S.G., Kennedy, J.L., Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet. 2002 Oct 1;11(20):2517-30 Blaisdell, J., Mohrenweiser, H., Jackson, Ferguson, J., Coulter, S., Chanas, S., Chanas, B., Xi, T., Ghanayem, B., Goldstein, J.A. Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics. 2002 Dec;12(9):703- 11. Bosron, W.F., Ting-Kai, L., (1986). “Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases, and their relationship to alcohol metabolism and alcoholism.” Hepatology 6(3): 502 – 510. Bradford, L.D., CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002 Mar;3 (2):229- 43. Brockmoller, J., et.al. Pharmacogenetic diagnosis of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenetics. 2000:1:125-51. Budziszewska B, Szymanska M, Leskiewicz M, Basta-Kaim A, Jaworska- Feil L, Kubera M, Jantas D, Lason W. The decrease in JNK- and p38-MAP kinase activity is accompanied by the enhancement of PP2A phosphate level in the brain of prenatally stressed rats. J Physiol Pharmacol. 2010 Apr;61(2):207-15. Carter CJ. Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. Neurochem Int. 2007 Feb;50(3):461-90. Epub 2007 Jan 18. Review. Ceriello, A., Giugliano, D., Quatraro, A., Lefebvre, P.J., Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci 1991;81:739-42. Chang, T.K., et al. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 57(10):1946-54. Chango, A., Boisson, F., et al. (2000). “The effect of 677C-->T and 1298A-->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects.” Br J Nutr 83(6): 593-6. Charradi K, Sebai H, Elkahoui S, Ben Hassine F, Limam F, Aouani E. Grape Seed Extract Alleviates High-Fat Diet-Induced Obesity and Heart Dysfunction by Preventing Cardiac Siderosis. Cardiovasc Toxicol. 2011 Jan 14. Cheng, T., Zhu, Z., et al. (2001). “Effects of multinutrient supplementation on antioxidant defense systems in healthy human beings.” J Nutr Biochem 12(7): 388- 395. Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., Kamataki, T., Detection of three genetic polymorphisms in the 5’- flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res. 1999 Sep;90(9):899-902 Chistyakov, D. A., Savost’anov, et al. (2001). “Polymorphisms in the Mn-SOD and EC-SOD genes and their relationship to diabetic neuropathy in type 1 diabetes mellitus.” BMC Med Genet 2(1): 4. Cosma, G., Crofts, F., et al. (1993). “Relationship between genotype and function of the human CYP1A1 gene.” J Toxicol Environ Health 40(2-3): 309-16. Cozza, K.L., Armstrong, S.C., Oesterheld, J.R., Drug Interaction principles for Medical Practice. American Psychiatric Publishing Inc. (2003) Chuang DM. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol. 2004;16(1-2):83-90. Review. Das J et al. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010; 44(3): 340-55. Gao N, Budhraja A, Cheng S, Yao H, Zhang Z, Shi X. Induction of apoptosis in human leukemia cells by grape seed extract occurs via activation of c-Jun NH2- terminal kinase. Clin Cancer Res. 2009 Jan 1;15(1):140- 9. Ho, P.C., et al. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 2003; 3(6):335-42. Jeong SW, Kim LS, Hur D, Bae WY, Kim JR, Lee JH. Gentamicin-induced spiral ganglion cell death: apoptosis mediated by ROS and the JNK signaling pathway. Acta Otolaryngol. 2010 Jun;130(6):670- 8. Lam, Y.W.F., Gaedigk, A., Ereshefsy, L., et al: CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002;22:1001-1006. Lichtenstein AH, Appel LJ, Brands M et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation, 2006; 114: 82-96. Lin CL, Lin JK. Epigallocatechin gallate (EGCG) attenuates high glucose-induced insulin signaling blockade in human hepG2 hepatoma cells. Mol Nutr Food Res. 2008; 52(8): 930-9. Liu H, Xiao Y, Xiong C, Wei A, Ruan J. Apoptosis induced by a new flavonoid in human hepatoma HepG2 cells involves reactive oxygen species-mediated mitochondrial dysfunction and MAPK activation. Eur J Pharmacol. 2011 Jan 15. Madhyastha R, Madhyastha H, Nakajima Y, Omura S, Maruyama M. Curcumin Facilitates Fibrinolysis and Cellular Migration during Wound Healing by Modulating Urokinase Plasminogen Activator Expression. Pathophysiol Haemost Thromb. 2010 Nov 12 Maheshwari A, Misro MM, Aggarwal A, Sharma RK, Nandan D. N-Acetyl-L- cysteine counteracts oxidative stress and prevents H(2) O(2) induced germ cell apoptosis through down-regulation of caspase-9 and JNK/c-Jun. Mol Reprod Dev. 2010 Dec 22. doi: 10.1002/mrd.21268. Moon et al. Inhibitory effect of (-)- epigallocatechin-3-gallate on lipid accumulation of 3T3-L1 cells. Obesity (Silver Spring). 2007; 15(11): 2571-82. Pan J, Xiao Q, Sheng CY, Hong Z, Yang HQ, Wang G, Ding JQ, Chen SD. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson’s disease. Neurochem Int. 2009 Jun;54(7):418-25. Epub 2009 Jan 29. Ramerstorfer J, Furtmüller R, Sarto- Jackson I, Varagic Z, Sieghart W, Ernst M. The GABAA Receptor malpha?+ebetaS- Interface: A Novel Target for Subtype Selective Drugs. J Neurosci. 2011 Jan 19;31(3):870-7 Romier-Crouzet B, Van De Walle J, During A, Joly A, Rousseau C, Henry O, Larondelle Y, Schneider YJ. Inhibition of inflammatory mediators by polyphenolic plant extracts in human intestinal Caco-2 cells. Food Chem Toxicol. 2009 Jun;47(6):1221-30. Epub 2009 Feb 20. Spiliotaki M, Salpeas V, Malitas P, Alevizos V, Moutsatsou P. Altered glucocorticoid receptor signaling cascade in lymphocytes of bipolar disorder patients. Psychoneuroendocrinology. 2006 Jul;31(6):748-60. Epub 2006 Apr 18. Stornetta RL, Zhu JJ. Ras and Rap Signaling in Synaptic Plasticity and Mental Disorders. Neuroscientist. 2010 Apr 29. Tian H, Zhang G, Li H, Zhang Q. Antio xidant NAC and AMPA/KA receptor antagonist DNQX inhibited JNK3 activation following global ischemia in rat hippocampus. Neurosci Res. 2003 Jun;46(2):191-7. Waltner-Low ME et al. Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem. 2002; 277(38): 34933-40. Wu H et al. JNK-dependent NFATc1 pathway positively regulates IL-13 gene expression induced by (-)- epigallocatechin-3-gallate in human basophilic KU812 cells. Free Radic Biol Med. 2009; 47(7): 1028-38. Wu N et al. Taurine prevents free fatty acid-induced hepatic insulin resistance in association with inhiditing JNK1 activation and improving insulin signaling in vitro. Diabetes Res Clin Pract. 2010; 90(3): 288-90. Xie N, Wang C, Lin Y, Li H, Chen L, Zhang T, Sun Y, Zhang Y, Yin D, Chi Z. The role of p38 MAPK in valproic acid induced microglia apoptosis. Neurosci Lett. 2010 Sep 20;482(1):51-6. Epub 2010 Jul 16. Xu Y, Hou XY, Liu Y, Zong YY. Different protection of K252a and N- acetyl-L- cysteine against amyloid-beta peptide- induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades. J Neurosci Res. 2009 Mar;87(4):918-27. Yaniv SP, Lucki A, Klein E, Ben- Shachar D. Dexamethasone enhances the norepinephrine-induced ERK/MAPK intracellular pathway possibly via dysregulation of the alpha2-adrenergic receptor: implications for antidepressant drug mechanism of action. Eur J Cell Biol. 2010 Sep;89(9):712-22. Zhang F, Lau SS, Monks TJ. The Cytoprotective Effect of N-acetyl-L- cysteine against ROS-induced Cytotoxicity is Independent of its Ability to Enhance Glutathione Synthesis. Toxicol Sci. 2010 Dec 6.